Surfactant therapy improves pulmonary function in infants with Pneumocystis carinii pneumonia and acquired immunodeficiency syndrome.

NLM AIDSLINE
Surfactant therapy improves pulmonary function in infants with Pneumocystis carinii pneumonia and acquired immunodeficiency syndrome.
Creery WD; Hashmi A; Hutchison JS; Singh RN; Department of Pediatrics,
March 30, 1998
Pediatr Pulmonol. 1997 Nov;24(5):370-3. Unique Identifier : AIDSLINE

Pneumocystis carinii pneumonia (PCP) is an important cause of acute respiratory failure in HIV-infected children. PCP may initiate acute respiratory distress syndrome (ARDS) by adversely affecting surfactant physiology. We report improved pulmonary function following administration of bovine lipid extract surfactant to two infants with AIDS-related PCP/ARDS.

*AIDS-Related Opportunistic Infections/DRUG THERAPY *Pneumonia, Pneumocystis carinii/DRUG THERAPY *Pulmonary Surfactants/THERAPEUTIC USE *Respiratory Distress Syndrome/DRUG THERAPY

www.aegis.org